Category

News Short

News posts – title only before “More”

Sound Pharma initiates enrollment in pivotal Phase 3 clinical trial of SPI-1005 for the treatment of hearing loss and tinnitus in Meniere’s disease

By News Short

Sound Pharmaceuticals is pleased to announce that it has enrolled the first patient in its Phase 3 clinical trial involving SPI-1005 for the Treatment of Meniere’s Disease (STOPMD-3). Additionally, this marks the first Phase 3 trial of an investigational new drug for the treatment of Meniere’s Disease (MD).
Read More

Sound Pharmaceuticals’ NIH Grant for a novel oral COVID-19 treatment increases to $4.2M

By News Short

Sound Pharmaceuticals, Inc. (SPI) is pleased to announce that is has received a $1.1M supplement to its $3.1M National Center for Advancing Translational Sciences (NCATS) Award, bringing the total NIH funding to $4.2M. SPI is developing ebselen (SPI-1005), a new molecular entity with anti-viral and anti-inflammatory activity, and enrolling two Phase 2 clinical trials for the treatment of hospitalized COVID-19 patients.
Read More